Treating and Controlling Glaucoma

Selective laser trabeculoplasty, commonly called SLT, is now considered a first-line treatment option for open-angle glaucoma, which is the most common form of the condition. During the procedure, a low-energy laser is aimed at the drainage tissue inside the eye to help fluid flow out more freely. The visit is brief, numbing drops are used so most patients feel little to no discomfort, and there is no incision. The pressure-lowering effect builds over a few weeks and can last several years. SLT can be repeated if the benefit fades, and it works well on its own or alongside drops.

Minimally invasive glaucoma surgery, known as MIGS, refers to a group of procedures that use tiny instruments or very small incisions to create new drainage pathways inside the eye. These procedures are shorter than traditional glaucoma surgery, carry fewer risks, and allow for faster recovery. MIGS is generally best suited for mild to moderate glaucoma and is most often performed at the same time as cataract surgery. After a successful MIGS procedure, many patients are able to reduce or discontinue their daily eye drops, which simplifies their routine and removes the burden of strict dosing schedules.

When drops and laser treatment are not sufficient to keep pressure at a safe level, traditional surgery may become necessary. Trabeculectomy creates a new opening in the eye wall so fluid can drain out through a small reservoir under the eyelid. Tube shunt surgery places a tiny flexible tube that redirects fluid to a collection reservoir on the outer surface of the eye. Both procedures can lower pressure more substantially than drops or laser alone. Recovery takes longer and carries a higher risk of complications, so these options are typically reserved for cases where other treatments have not worked well enough. Regular follow-up visits after surgery are important to make sure the drainage pathway stays open and pressure remains stable.

A newer approach involves tiny implants placed inside the eye during a brief in-office procedure. Some of these implants release a pressure-lowering medication continuously for an extended period, reducing or eliminating the need for daily drops during that time. This can be a meaningful benefit for patients who struggle to maintain a consistent drop schedule. Additional implant designs are in development and being studied for safety and effectiveness. Your provider can explain whether you might be a candidate for this type of treatment based on your specific situation.

With current treatments, damage that has already occurred to the optic nerve cannot be repaired. All available therapies are designed to slow or stop further loss, not to restore what has already been affected. This is why starting treatment early, ideally before significant damage has occurred, gives the best chance of preserving good vision for the long term. It is also why routine eye exams are important even when you have no symptoms, since glaucoma often causes no pain or noticeable changes in the early stages.

The optic nerve is vulnerable to damage when pressure inside the eye remains too high for too long. Eye drops lower that pressure either by reducing how much fluid the eye produces or by helping fluid drain out more efficiently. Keeping pressure at or below the target level reduces the mechanical stress on nerve fibers, which slows the rate at which they are lost. Consistent daily use is essential because the protective effect depends on pressure staying within a safe range around the clock, not just at the time of your office visit.

That depends on the individual. Some patients achieve enough pressure reduction from laser treatment that drops are no longer needed, at least for a period of time. Others still require one or more medications after the procedure to reach their pressure goal. The outcome depends on how high pressure was before treatment, the specific type of glaucoma, and how your eye responds. Your provider will monitor pressure closely after the procedure and guide the decision about whether drops can be reduced or discontinued.

Because glaucoma typically has no symptoms in its early and middle stages, changes in pressure or nerve structure are often detected through testing before a patient notices any difference in vision. A rising pressure reading, new changes on a visual field test, or thinning visible on an OCT scan may indicate that a treatment adjustment is needed. This is one of the most important reasons to keep all scheduled follow-up appointments. If you are experiencing side effects that cause you to miss doses, report this to your provider right away, because inconsistent use can allow pressure to creep upward without your awareness.

Cataract surgery is generally safe for patients with glaucoma and in some cases can actually lead to a modest reduction in eye pressure on its own. Many surgeons take the opportunity to combine cataract removal with a MIGS procedure in a single session, which can address both conditions at once. After a successful combined procedure, some patients are able to reduce or discontinue their glaucoma drops. Whether this approach is appropriate depends on the type and stage of your glaucoma, the severity of the cataract, and your overall eye health. Your care team will walk you through the risks and benefits so you can make a fully informed decision.